Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced the appointment of Joseph Vazzano as Vice...
-
NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
-
NEW YORK, June 30, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today that it has completed its initial...
-
NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today the pricing of its initial public offering of...
-
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notice of Allowance has now been received from the...
-
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notices of Allowance have now been received from the...
-
NEW YORK, Dec. 30, 2015 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company, announced that it filed a registration statement on Form 10 with...